Related Experiment Videos
[Cost analysis concerning MRSA-infection in ICU].
G Geldner1, M Ruoff, H J Hoffmann
1Universitätsklinik für Anästhesiologie, Universität Ulm. goetz.geldner@medizin.uni-ulm.de
Summary
Rising MRSA infections incur significant costs for intensive care units (ICUs). Additional financial support is crucial for treating MRSA patients to maintain quality standards and reduce overall economic burden.
Area of Science:
- Infectious Diseases
- Healthcare Economics
- Intensive Care Medicine
Context:
- Methicillin-resistant Staphylococcus aureus (MRSA) infection rates are increasing globally.
- Inadequate financial support exists for treating MRSA-infected patients, despite high incidence rates in some European ICUs (up to 30%).
- Antimicrobial drug misuse in humans and animals contributes to the rise of MRSA.
Purpose:
- To investigate the financial costs associated with MRSA infections in an intensive care unit (ICU).
- To quantify the direct treatment expenses and indirect costs (e.g., bed closures) related to MRSA patient management.
- To evaluate the economic impact of MRSA on ICU operations and healthcare systems.
Summary:
- MRSA infections result in substantial average monthly costs of approximately 3848 EURO for decontamination/treatment and 5560 EURO for fixed costs.
- MRSA patients require an average of 5.8 additional ICU days per month, leading to a financial loss of 1622 EURO per patient day.
- These losses exceed double the reimbursement rate for standard ICU patient days.
Impact:
- Implementing additional financial support for MRSA-infected patients is recommended to ensure quality of care.
- Calculating and reimbursing these extra costs can lead to reduced overall economic expenditure on MRSA treatment.
- This study highlights the urgent need for revised healthcare economic policies to address the financial challenges posed by MRSA.